盐酸多奈哌齐治疗血管性痴呆的临床研究

目的评价盐酸多奈哌齐治疗血管性痴呆患者的安全性和有效性。方法对62例VD患者随机分为两组,治疗组30例(男性20例,女性10例),平均年龄(78±6)岁和对照组32例(男性22例,女性10例),平均年龄(77±7)岁,进行12周临床观察。用MMSE为主要评价指标,日常生活能力量表(ADL)和临床痴呆程度量表(CDR)为次要评价指标。结果5mg/d盐酸多奈哌齐治疗12周时,盐酸多奈哌齐组较对照组安慰剂MMSE、ADL、CDR分数显著改善(依次P<0.01,P<0.05,P<0.01)。对照组安慰剂,研究结果显示,5mg/d盐酸多奈哌齐治疗12周时,治疗后较治疗前MMSE、CDR、ADL分数分别较明显改善(P<0.05)。安慰剂组评价指标无改善。结论盐酸多奈哌齐可显著改善VD患者的认知功能,且安全性良好。

The clinical study of Aricept in the treatment vascalar dementia

Objective To evaluate the efficicency and safety of Aricepc for mild, moderate vein dementia(VD) Methods 62 eftses of patients with mild, middle VD were randomly divided into 2 groups: the treated group and the control group. Taking 12 weeks clinical therapy.MMSE was taken as the main value target and ADL,CDR were as the secondary value target. Results After 12 weeks, the marks of MMSE, AOL, CDR of the treatment group were more improved than that of the control group(P<0.01,P<0.05,P<0.01). The study indicated that the marks of MMSE, ADL, CDR have been improved(P<0.05). Conclusion Aricepwhich can prominently improve the perceive function,the degree of dementia and the ability of taking care of oneself, is one of the efficiency ways in the treatment of VD, morever, its security and endurance is good.